Bicycle Therapeutics (BCYC) Competitors $7.42 -0.02 (-0.20%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. APGE, CGON, AGIO, INDV, IRON, BLTE, IDYA, HRMY, ADPT, and SPRYShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Apogee Therapeutics (APGE), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Indivior (INDV), Disc Medicine (IRON), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors Apogee Therapeutics CG Oncology Agios Pharmaceuticals Indivior Disc Medicine Belite Bio IDEAYA Biosciences Harmony Biosciences Adaptive Biotechnologies ARS Pharmaceuticals Apogee Therapeutics (NASDAQ:APGE) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings. Which has higher earnings & valuation, APGE or BCYC? Bicycle Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$3.60-13.16Bicycle Therapeutics$35.28M14.57-$169.03M-$3.14-2.36 Do insiders & institutionals have more ownership in APGE or BCYC? 79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 42.8% of Apogee Therapeutics shares are held by company insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is APGE or BCYC more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -790.07%. Bicycle Therapeutics' return on equity of -25.54% beat Apogee Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -28.35% -26.98% Bicycle Therapeutics -790.07%-25.54%-21.23% Do analysts rate APGE or BCYC? Apogee Therapeutics currently has a consensus target price of $95.80, suggesting a potential upside of 102.20%. Bicycle Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 236.70%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Which has more risk & volatility, APGE or BCYC? Apogee Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Does the media favor APGE or BCYC? In the previous week, Apogee Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Apogee Therapeutics and 2 mentions for Bicycle Therapeutics. Apogee Therapeutics' average media sentiment score of 0.20 beat Bicycle Therapeutics' score of 0.19 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicycle Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBicycle Therapeutics beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$514.18M$2.90B$5.50B$9.01BDividend YieldN/A2.64%5.39%4.11%P/E Ratio-2.3621.5027.4220.07Price / Sales14.57282.64398.50109.13Price / CashN/A41.4736.1356.90Price / Book0.657.518.015.70Net Income-$169.03M-$55.05M$3.16B$248.47M7 Day Performance1.99%3.05%2.08%2.92%1 Month Performance-10.54%5.80%4.38%5.77%1 Year Performance-62.08%6.15%35.81%21.39% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics4.1383 of 5 stars$7.43-0.2%$25.00+236.7%-62.4%$514.18M$35.28M-2.36240News CoverageAPGEApogee Therapeutics2.7454 of 5 stars$43.43+0.1%$94.60+117.8%+16.0%$2.00BN/A0.0091Analyst ForecastHigh Trading VolumeCGONCG Oncology2.7456 of 5 stars$26.00+0.2%$58.67+125.6%-14.8%$1.98B$1.14M0.0061AGIOAgios Pharmaceuticals4.076 of 5 stars$33.26-0.6%$58.60+76.2%-15.9%$1.94B$36.50M2.96390INDVIndivior2.0701 of 5 stars$14.74+5.7%$17.00+15.3%+0.9%$1.92B$1.19B8.161,051Analyst ForecastHigh Trading VolumeIRONDisc Medicine2.1831 of 5 stars$52.96-2.8%$96.70+82.6%+27.8%$1.89BN/A0.0030Positive NewsAnalyst ForecastBLTEBelite Bio2.6885 of 5 stars$57.70-2.3%$96.67+67.5%+24.9%$1.88BN/A0.0010News CoveragePositive NewsAnalyst ForecastGap UpIDYAIDEAYA Biosciences3.6765 of 5 stars$21.02-1.6%$53.42+154.1%-35.0%$1.87B$7M-5.8680HRMYHarmony Biosciences4.8324 of 5 stars$31.60-1.2%$53.63+69.7%+7.0%$1.84B$714.73M12.06200Positive NewsADPTAdaptive Biotechnologies3.4705 of 5 stars$11.65-1.2%$10.57-9.3%+240.7%$1.79B$178.96M-12.14790News CoverageSPRYARS Pharmaceuticals2.9613 of 5 stars$17.45-4.1%$31.00+77.7%+93.4%$1.79B$89.15M0.0090Insider TradeHigh Trading Volume Related Companies and Tools Related Companies Apogee Therapeutics Competitors CG Oncology Competitors Agios Pharmaceuticals Competitors Indivior Competitors Disc Medicine Competitors Belite Bio Competitors IDEAYA Biosciences Competitors Harmony Biosciences Competitors Adaptive Biotechnologies Competitors ARS Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
